MX2019010895A - Formulacion liquida de anticuerpo anti-tnf alfa. - Google Patents

Formulacion liquida de anticuerpo anti-tnf alfa.

Info

Publication number
MX2019010895A
MX2019010895A MX2019010895A MX2019010895A MX2019010895A MX 2019010895 A MX2019010895 A MX 2019010895A MX 2019010895 A MX2019010895 A MX 2019010895A MX 2019010895 A MX2019010895 A MX 2019010895A MX 2019010895 A MX2019010895 A MX 2019010895A
Authority
MX
Mexico
Prior art keywords
liquid formulation
tnf alpha
alpha antibody
antibody
tnf
Prior art date
Application number
MX2019010895A
Other languages
English (en)
Inventor
Yun Sora
Kyung Ko Youn
Eon So Jin
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63522490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019010895(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MX2019010895A publication Critical patent/MX2019010895A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464436—Cytokines
    • A61K39/464438—Tumor necrosis factors [TNF], CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una formulación líquida de un anticuerpo contra TNF-a, específicamente a una formulación líquida de adalimumab.
MX2019010895A 2017-03-16 2018-03-16 Formulacion liquida de anticuerpo anti-tnf alfa. MX2019010895A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170033188 2017-03-16
PCT/KR2018/003097 WO2018169348A1 (ko) 2017-03-16 2018-03-16 항-tnf 알파 항체의 액상 제제

Publications (1)

Publication Number Publication Date
MX2019010895A true MX2019010895A (es) 2019-11-05

Family

ID=63522490

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010895A MX2019010895A (es) 2017-03-16 2018-03-16 Formulacion liquida de anticuerpo anti-tnf alfa.

Country Status (15)

Country Link
JP (2) JP7109849B2 (es)
KR (2) KR20180106974A (es)
CN (1) CN110621303A (es)
AU (1) AU2018236651B2 (es)
BR (1) BR112019019162A2 (es)
CO (1) CO2019010860A2 (es)
MA (1) MA46988A1 (es)
MX (1) MX2019010895A (es)
MY (1) MY197202A (es)
NZ (1) NZ757965A (es)
PH (1) PH12019502075A1 (es)
RU (1) RU2756619C2 (es)
UA (1) UA123847C2 (es)
WO (1) WO2018169348A1 (es)
ZA (1) ZA201906696B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021015034A2 (pt) * 2019-02-18 2021-10-05 Eli Lilly And Company Formulação de anticorpo terapêutico
TW202102260A (zh) * 2019-03-21 2021-01-16 美商再生元醫藥公司 含有抗ｉｌ－３３抗體之穩定調配物
US20230173068A1 (en) * 2020-02-20 2023-06-08 Bio-Thera Solutions, Ltd. ANTI-TNF-a ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR AND USE THEREOF

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2815689C (en) * 2010-11-11 2016-11-22 Abbvie Biotechnology Ltd. Improved high concentration anti-tnf.alpha. antibody liquid formulations
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
KR20160105535A (ko) * 2012-03-07 2016-09-06 카딜라 핼쓰캐어 리미티드 TNF-α 항체의 약제학적 제형
BR112015004984A2 (pt) 2012-09-07 2017-07-04 Coherus Biosciences Inc formulações aquosas estáveis de adalimumab
CN105051064A (zh) * 2013-01-24 2015-11-11 葛兰素史克知识产权开发有限公司 抗TNF-α抗原结合蛋白
CN105025925A (zh) 2013-03-15 2015-11-04 拜尔健康护理有限责任公司 抗-催乳素受体抗体制剂
WO2015134406A1 (en) 2014-03-03 2015-09-11 La Jolla Biologics, Inc. Stable aqueous recombinant protein formulations
WO2015151115A1 (en) * 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Liquid pharmaceutical composition of adalimumab
LT2946765T (lt) * 2014-05-23 2016-11-25 Ares Trading S.A. Skysta farmacinė kompozicija
US9821059B2 (en) 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
WO2016120413A1 (en) * 2015-01-28 2016-08-04 Mabxience S.A. Pharmaceutical formulations for anti-tnf-alpha antibodies
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody

Also Published As

Publication number Publication date
AU2018236651A1 (en) 2019-10-31
MY197202A (en) 2023-05-31
AU2018236651B2 (en) 2020-12-10
ZA201906696B (en) 2020-08-26
BR112019019162A2 (pt) 2020-04-14
KR20180106974A (ko) 2018-10-01
MA46988A1 (fr) 2020-06-30
RU2019130728A3 (es) 2021-04-16
JP2022097600A (ja) 2022-06-30
CO2019010860A2 (es) 2020-01-17
KR20200096472A (ko) 2020-08-12
UA123847C2 (uk) 2021-06-09
RU2756619C2 (ru) 2021-10-04
WO2018169348A1 (ko) 2018-09-20
CN110621303A (zh) 2019-12-27
PH12019502075A1 (en) 2020-09-14
NZ757965A (en) 2022-07-01
KR102342292B1 (ko) 2021-12-24
JP7109849B2 (ja) 2022-08-01
JP2020510079A (ja) 2020-04-02
RU2019130728A (ru) 2021-04-16

Similar Documents

Publication Publication Date Title
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
EP4257613A3 (en) Bispecific checkpoint inhibitor antibodies
MY198059A (en) Anti-ox40 antibodies and their uses
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
PH12018502456A1 (en) Anti-cd04 antibodies and their uses
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
MY191581A (en) Anti-pd-1 antibodies
WO2016061389A3 (en) Anti-alpha-synuclein antibodies and methods of use
MY193661A (en) Anti-tim3 antibodies and methods of use
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
SG10201902326XA (en) Mk2 inhibitors and uses thereof
MX2023006416A (es) Anticuerpos, usos y metodos.
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
MX2019010367A (es) Formulacion acuosa de anticuerpo anti ligando 1 de muerte programada (pd-l1).
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
PH12019502075A1 (en) A liquid formulation of anti-tnf alpha antibody
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
AU2018279184A1 (en) Anti-TrkB antibodies
MX2020006758A (es) Cemento de alumina.
MX2018009218A (es) Anticuerpos de cgrp y sus usos.
MX2017016258A (es) Antigenos de leucemia mieloide aguda (aml) y usos de los mismos.